深夜！李嘉诚回应！

Group 1 - The core viewpoint of the article revolves around the response from Cheung Kong Holdings regarding the port transaction, emphasizing that the transaction will not occur under any illegal or non-compliant circumstances [4] - The company stated that the completion of the transaction depends on a series of conditions, including legal and regulatory approvals, and necessary shareholder approvals [4][5] - The transaction involves the sale of core assets of its global port business, covering 43 ports across 23 countries, including a 90% stake in the Panama port company [5][6] Group 2 - The Chinese government, through the Ministry of Foreign Affairs and the State Administration for Market Regulation, has expressed concerns about the transaction and will conduct a legal review to ensure compliance with national interests [5][7] - The Hong Kong Chief Executive has acknowledged public concerns regarding the transaction and emphasized the need for compliance with legal and regulatory requirements [7] - The article highlights public sentiment against the sale, with some viewing it as a betrayal of national interests [6] Group 3 - The article also discusses a controversial policy initiated by former President Trump aimed at reducing drug prices by linking U.S. government payments for certain drugs to lower prices abroad [9][11] - The policy is expected to impact the pharmaceutical industry significantly, with estimates suggesting potential losses of up to $1 trillion over ten years for drug companies [18] - Experts have raised concerns that the policy may not effectively lower drug prices and could lead to reduced innovation in the pharmaceutical sector [19][20]